peptide-information

Purity is one of the few properties of a synthetic peptide that can be measured directly, yet the single number printed on a label hides a chain of assumptions about how it was generated. This article examines how researchers separate, quantify, and identify the contents of a peptide preparation, and why the appropriate purity grade depends entirely on the intended experiment.

Why purity is a research variable, not a marketing number

Synthetic peptides have become a large and growing class of research tools and pharmaceutical candidates, with new peptide drugs approved by regulators most years and thousands more studied preclinically.¹ In an experimental setting, the purity of a preparation is not a badge of quality so much as a controlled variable. A tube described as “98% pure” still contains, in principle, up to two percent of other species — truncated chains, modified side products, residual salts, or water — and whether that fraction matters depends on what the material is used for.

The reason this matters is that impurities are not always inert. In studies of therapeutic-grade preparations, analytical teams have repeatedly found that minor species carry their own structural and functional properties: aberrant disulfide (trisulfide) bonds in recombinant proteins, for example, can be measured by liquid chromatography–mass spectrometry and shown to shift stability and purity readouts even when folding and receptor binding appear unchanged.¹⁰ A researcher who treats a preparation as if it were a single pure compound, when it is in fact a mixture, risks attributing an effect to the target sequence that actually belongs to a contaminant. Purity verification is therefore part of experimental hygiene, in the same category as confirming a cell line’s identity or a reagent’s lot number.

Where impurities come from: the synthesis

Most research peptides are assembled by solid-phase peptide synthesis (SPPS), the approach introduced by Merrifield in which the growing chain stays anchored to an insoluble resin while amino acids are added one at a time.² Each cycle involves deprotecting the terminal amino group, coupling the next protected amino acid, and washing away excess reagents. The dominant modern strategy uses fluorenylmethyloxycarbonyl (Fmoc) protection, and although the chemistry is highly optimized, every cycle is an opportunity for a small fraction of chains to go astray.³

The characteristic by-products of SPPS are well documented. Incomplete coupling leaves “deletion” sequences missing one or more residues; incomplete deprotection can cap a chain prematurely; and side reactions during synthesis or cleavage generate modified variants. A particularly studied example is aspartimide formation, a base-mediated rearrangement at aspartate-containing sequences that can spawn several related impurities and has driven an entire literature on protecting-group and additive strategies to suppress it.⁴ Longer or more hydrophobic sequences compound the problem, and poor aqueous solubility can itself complicate both synthesis and downstream handling.⁵ After cleavage from the resin, the crude material is usually purified by preparative chromatography, but no purification is perfect — which is precisely why the finished material has to be characterized rather than assumed clean.

Reversed-phase HPLC: separating and quantifying

High-performance liquid chromatography (HPLC) is the workhorse for estimating how much of a preparation is the intended sequence. In the reversed-phase mode used for most peptides, the sample is pushed through a column packed with a hydrophobic stationary phase while a mobile phase of increasing organic solvent content flows past. Molecules partition between the two phases according to their hydrophobicity and elute at different times, producing a chromatogram of peaks plotted against retention time.⁶

Purity is then reported as the area of the main peak divided by the total area of all detected peaks, usually with ultraviolet detection at a wavelength such as 214 nm where the peptide backbone absorbs. This is a relative measurement, and it carries important caveats. The number depends on the column chemistry, the gradient, the flow rate, the injection amount, and the detection wavelength, so the same sample can yield different purity figures under different methods. Chromatographic behaviour can also be sensitive to conditions: in one study of a synthetic peptide drug, peak shape degraded badly above pH 5.8, and a complementary technique — capillary electrophoresis — was needed to resolve equilibrium impurities that HPLC handled poorly at higher pH.⁷

The most consequential limitation is co-elution: an impurity that happens to share the target’s retention time hides underneath the main peak and inflates the apparent purity. A quality-control investigation of a radiolabeled peptide conjugate made this concrete, showing that two HPLC methods gave different answers and that one setup could overestimate radiochemical purity until a mass-spectrometric method identified the hidden side product.⁸ The practical lesson is that a chromatographic purity value is a strong signal but not a proof of homogeneity, which is why it is paired with an orthogonal technique.

Mass spectrometry: confirming identity and mass

Chromatography tells a researcher that most of a sample is a single, well-resolved species; it does not confirm that the species is the correct sequence. Mass spectrometry (MS) answers that second question. The instrument ionizes the molecules, sorts the resulting ions by their mass-to-charge ratio (m/z), and records a spectrum from which the molecular mass can be reconstructed. Comparing the observed mass to the theoretical mass calculated from the intended sequence is the core identity check.⁶

Two ionization methods dominate peptide work. Electrospray ionization (ESI) produces a series of multiply charged ions and integrates naturally with liquid chromatography, so an LC–MS run can separate and mass-measure components in a single experiment; tandem MS (MS/MS) can go further and read sequence information from fragmentation patterns.⁶ Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS, in which the analyte is co-crystallized with a light-absorbing matrix and desorbed by a laser pulse, is a fast, robust way to obtain an intact mass.¹¹ Used together, HPLC and MS are complementary: chromatography quantifies, mass spectrometry identifies, and the combination is far more informative than either alone.

The power of pairing the two is visible whenever analysts profile a supposedly well-defined preparation in detail. In a mass-spectrometric characterization of a highly purified gonadotropin product, LC–MS/MS peptide mapping resolved the sample into its components and estimated that protein impurities made up roughly 20–30% of the total protein content, alongside substantial oxidized forms — a level of structural detail no single purity percentage could convey.⁹ Modern research peptides such as BPC-157 and TB-500 are routinely accompanied by both a chromatogram and a mass spectrum for exactly this reason.

How much purity is enough? Matching grade to application

There is no universal “correct” purity. Higher purity is generally preferable and is appropriate for any use with a lower requirement, but pushing purity higher costs yield and money, so the sensible target is set by the experiment. Quantitative and structural work — binding constants, enzyme kinetics, crystallography, calibration standards — is sensitive to contaminants and typically calls for the highest grades. Qualitative or screening work can often tolerate more heterogeneity. The table below summarizes commonly cited purity tiers and the kinds of research applications each is generally considered suitable for; treat it as orientation, not prescription, and confirm requirements against the specific protocol and any applicable standards.

Because a preparation of a given purity satisfies any application with a lower threshold, a laboratory that standardizes on high-purity material simplifies its own decision-making. What the tiers cannot capture is the identity dimension: an 85%-pure preparation of the correct sequence is a different object from an 85%-pure preparation of the wrong one, which returns the discussion to the necessity of mass-spectrometric confirmation.

Beyond the purity number: content, salts, and contaminants

A chromatographic purity percentage describes the relative abundance of species that the method detects — it is silent on several other properties that can dominate an experiment. Peptide content (the fraction of the dry mass that is actually peptide, as opposed to water and salt) is often 70–90% and is a separate measurement; two vials of identical HPLC purity can differ substantially in how much peptide they deliver per milligram.

Counter-ions are another blind spot. Peptides purified by reversed-phase HPLC are commonly isolated as trifluoroacetate (TFA) salts, and the associated TFA is not visible as an impurity peak in a standard UV chromatogram; dedicated methods such as capillary electrophoresis with indirect detection are used to quantify it.⁶ Residual solvents and water similarly sit outside the purity figure. And for work involving cells or animals, endotoxin and other biological contaminants are assessed by their own assays entirely. None of these is captured by the headline percentage, which is why a thorough characterization reports multiple orthogonal parameters rather than one.

It is worth stating plainly what all of this analytical work does not establish. Purity, identity, content, and salt form describe the chemistry of what is in the vial. They do not measure biological activity, potency, or any physiological effect, and they are not a safety evaluation. Those are distinct questions requiring distinct, functional experiments.

Reading a certificate of analysis

A certificate of analysis (COA) is the document that consolidates these measurements for a specific batch. A useful COA generally names the analytical method rather than only the result — for example, the HPLC column and gradient behind a purity figure, and the ionization mode behind a mass value — because, as the method-dependence of chromatography shows, a number without its method is difficult to interpret.⁸ Batch or lot identifiers matter too, since purity is a property of a particular preparation and cannot be inherited from a previous run.

When evaluating a COA, a few questions are worth asking: Does it report both a chromatographic purity and a mass-spectrometric identity, or only one? Is the reported mass an actual measured value close to the theoretical mass? Are peptide content and counter-ion listed separately from purity? Is the certificate tied to the lot in hand? A preparation accompanied by a transparent, method-level COA gives a researcher the information needed to judge fitness for a specific purpose — which is the entire point of characterizing a peptide in the first place.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.